SCHEMBL4025857

SCHEMBL4025857

CC(C)(C)OC(=O)C(O)Cc1ccc(O)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.47
ESR2 Q92731 4/20 0.47
CTSS P25774 1/20 0.47
CTSK P43235 1/20 0.47
LY96 Q9Y6Y9 1/20 0.45
SLC7A5 Q01650 1/20 0.42
TAAR1 Q96RJ0 3/20 0.42
SLC6A2 P23975 1/20 0.42
MIF P14174 1/20 0.41
ITGA4 P13612 1/20 0.41
ITGB7 P26010 1/20 0.41
BLM P54132 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.39
MDM4 O15151 1/20 0.39
MDM2 Q00987 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22442929 0.85 ADRB2 (0.40) SLC7A5ITGA4ITGB7
SCHEMBL487423 0.85 ITGA4 (0.51) CTSSCTSKSLC7A5ITGA4ITGB7
SCHEMBL487422 0.85 ITGA4 (0.51) CTSSCTSKSLC7A5ITGA4ITGB7
SCHEMBL30759366 0.85 ITGA4 (0.51) CTSSCTSKSLC7A5ITGA4ITGB7
SCHEMBL15697338 0.83 ESR1 (0.47) ESR1ESR2CTSSCTSKLY96
SCHEMBL8628683 0.83 ESR1 (0.47) ESR1ESR2CTSSCTSKLY96
SCHEMBL7464405 0.82 SLC7A5 (0.57) ESR1ESR2CTSSCTSKLY96
SCHEMBL16944167 0.82 ESR1 (0.46) ESR1ESR2CTSSCTSKLY96
SCHEMBL630703 0.82 SLC7A5 (0.57) ESR1ESR2CTSSCTSKLY96
SCHEMBL594571 0.82 SLC7A5 (0.57) ESR1ESR2CTSSCTSKLY96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes ZHU JIE 2009-08-27 US disclosed
US-7541470-B2 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. (US) 2009-06-02 US disclosed
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes SYNTHON IP INC. 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090216024-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 ESR1 2035/4885ESR2 1285/4885CTSS 1794/4885
US-20070167629-A1 Processes for making pioglitazone and compounds of the processes PDK4, PDK2, DPP4 ESR1 2035/4885ESR2 1285/4885CTSS 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.